Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Keros Therapeutics Inc (NASDAQ: KROS) closed the day trading at $10.86 up 3.23% from the previous closing price of $10.52. In other words, the price has increased by $3.23 from its previous closing price. On the day, 2.99 million shares were traded. KROS stock price reached its highest trading level at $11.63 during the session, while it also had its lowest trading level at $10.74.
Ratios:
For a better understanding of KROS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.03 and its Current Ratio is at 19.03. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On December 16, 2024, Oppenheimer reiterated its Outperform rating and also upped its target price recommendation from $102 to $63.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 439910336 and an Enterprise Value of -71487536. For the stock, the TTM Price-to-Sale (P/S) ratio is 676.78 while its Price-to-Book (P/B) ratio in mrq is 0.80. Its current Enterprise Value per Revenue stands at -109.812 whereas that against EBITDA is 0.352.
Stock Price History:
The Beta on a monthly basis for KROS is 1.44, which has changed by -0.80175245 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $9.77. The 50-Day Moving Average of the stock is -72.53%, while the 200-Day Moving Average is calculated to be -78.04%.
Shares Statistics:
Over the past 3-months, KROS traded about 1.23M shares per day on average, while over the past 10 days, KROS traded about 2814310 shares per day. A total of 39.26M shares are outstanding, with a floating share count of 32.86M. Insiders hold about 18.87% of the company’s shares, while institutions hold 83.39% stake in the company. Shares short for KROS as of 1735603200 were 4313793 with a Short Ratio of 3.50, compared to 1732838400 on 2197295. Therefore, it implies a Short% of Shares Outstanding of 4313793 and a Short% of Float of 14.499999999999998.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.35, with high estimates of -$1.18 and low estimates of -$1.55.
Analysts are recommending an EPS of between $0.31 and -$5.5 for the fiscal current year, implying an average EPS of -$4.12. EPS for the following year is -$3.64, with 12.0 analysts recommending between $2.06 and -$6.55.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $210.5M, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $32.05M. In the same quarter a year ago, actual revenue was $151k
